Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience

BACKGROUND: This retrospective study evaluates patient-reported outcomes in patients with multiple sclerosis (MS) spasticity who were treated with a cannabinoid oromucosal spray (Sativex®, USAN name: nabiximols) after not sufficiently responding to previous anti-spasticity medications. METHODS: Of 2...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :BMC Neurol
Главные авторы: D’hooghe, Marie, Willekens, Barbara, Delvaux, Valerie, D’haeseleer, Miguel, Guillaume, Daniel, Laureys, Guy, Nagels, Guy, Vanderdonckt, Patrick, Van Pesch, Vincent, Popescu, Veronica
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2021
Предметы:
Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8218396/
https://ncbi.nlm.nih.gov/pubmed/34157999
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-021-02246-0
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы